Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1998 1
2000 2
2001 4
2002 5
2003 12
2004 9
2005 5
2006 5
2007 12
2008 5
2009 12
2010 12
2011 16
2012 25
2013 16
2014 24
2015 29
2016 32
2017 25
2018 27
2019 40
2020 39
2021 34
2022 18
Text availability
Article attribute
Article type
Publication date

Search Results

356 results
Results by year
Filters applied: . Clear all
Page 1
Myelin-oligodendrocyte glycoprotein antibody-associated disease.
Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Alexopoulos H, Amato MP, Asgari N, Banwell B, Bennett J, Brilot F, Capobianco M, Chitnis T, Ciccarelli O, Deiva K, De Sèze J, Fujihara K, Jacob A, Kim HJ, Kleiter I, Lassmann H, Leite MI, Linington C, Meinl E, Palace J, Paul F, Petzold A, Pittock S, Reindl M, Sato DK, Selmaj K, Siva A, Stankoff B, Tintore M, Traboulsee A, Waters P, Waubant E, Weinshenker B, Derfuss T, Vukusic S, Hemmer B. Marignier R, et al. Among authors: aktas o. Lancet Neurol. 2021 Sep;20(9):762-772. doi: 10.1016/S1474-4422(21)00218-0. Lancet Neurol. 2021. PMID: 34418402 Review.
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: aktas o. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
[Ocrelizumab for treatment of multiple sclerosis].
Graf J, Albrecht P, Goebels N, Aktas O, Hartung HP. Graf J, et al. Among authors: aktas o. Nervenarzt. 2020 Aug;91(8):722-734. doi: 10.1007/s00115-020-00937-6. Nervenarzt. 2020. PMID: 32524163 Free PMC article. Review. German.
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B. Jarius S, et al. Among authors: aktas o. J Neuroinflammation. 2018 May 3;15(1):134. doi: 10.1186/s12974-018-1144-2. J Neuroinflammation. 2018. PMID: 29724224 Free PMC article. Review.
Diagnostic criteria for Susac syndrome.
Kleffner I, Dörr J, Ringelstein M, Gross CC, Böckenfeld Y, Schwindt W, Sundermann B, Lohmann H, Wersching H, Promesberger J, von Königsmarck N, Alex A, Guthoff R, Frijns CJ, Kappelle LJ, Jarius S, Wildemann B, Aktas O, Paul F, Wiendl H, Duning T; European Susac Consortium (EuSaC). Kleffner I, et al. Among authors: aktas o. J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1287-1295. doi: 10.1136/jnnp-2016-314295. Epub 2016 Oct 25. J Neurol Neurosurg Psychiatry. 2016. PMID: 28103199 Review.
Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.
Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, Hartung HP. Graf J, et al. Among authors: aktas o. Neurol Neuroimmunol Neuroinflamm. 2020 Dec 16;8(1):e919. doi: 10.1212/NXI.0000000000000919. Print 2021 Jan. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 33411674 Free PMC article. Review.
Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.
Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, Hartung HP. Graf J, et al. Among authors: aktas o. Neurol Neuroimmunol Neuroinflamm. 2020 Dec 16;8(1):e918. doi: 10.1212/NXI.0000000000000918. Print 2021 Jan. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 33406479 Free PMC article. Review.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Cree BAC, et al. Among authors: aktas o. Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5. Lancet. 2019. PMID: 31495497 Clinical Trial.
Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review.
Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, Jacob A, Kira JI, Leite MI, Marignier R, Miyamoto K, Palace J, Saiz A, Sepulveda M, Sveinsson O, Illes Z. Papp V, et al. Among authors: aktas o. Neurology. 2021 Jan 12;96(2):59-77. doi: 10.1212/WNL.0000000000011153. Epub 2020 Dec 11. Neurology. 2021. PMID: 33310876 Free PMC article.
356 results